Adaptimmune Therapeutics's market cap is currently $149.00M. The company's EPS TTM is $-0.214; its P/E ratio is ―; Adaptimmune Therapeutics is scheduled to report earnings on February 27, 2025, and the estimated EPS forecast is $-0.03. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 60.28M	$ 27.15M	$ 6.15M	$ 3.96M	$ 1.12M
Gross Profit	$ 50.42M	$ -100.58M	$ -104.94M	$ -87.61M	$ -96.38M
Operating Income	$ -138.04M	$ -163.97M	$ -162.25M	$ -133.41M	$ -139.77M
EBITDA	$ -128.20M	$ -155.59M	$ -155.68M	$ -125.81M	$ -131.76M
Net Income	$ -113.87M	$ -165.46M	$ -158.09M	$ -130.09M	$ -137.16M
Balance Sheet
Cash & Short-Term Investments	$ 146.94M	$ 204.60M	$ 369.58M	$ 368.22M	$ 89.54M
Total Assets	$ 282.62M	$ 328.92M	$ 469.55M	$ 451.14M	$ 181.54M
Total Debt	$ 25.23M	$ 23.08M	$ 25.47M	$ 23.71M	$ 25.46M
Net Debt	$ -118.76M	$ -84.96M	$ -124.48M	$ -33.17M	$ -24.95M
Total Liabilities	$ 243.10M	$ 247.04M	$ 263.58M	$ 109.92M	$ 57.91M
Stockholders' Equity	$ 39.51M	$ 81.88M	$ 205.96M	$ 341.23M	$ 123.64M
Cash Flow
Free Cash Flow	$ -145.76M	$ -171.51M	$ 1.95M	$ -56.50M	$ -115.58M
Operating Cash Flow	$ -140.88M	$ -141.77M	$ 10.73M	$ -53.59M	$ -112.51M
Investing Cash Flow	$ 176.54M	$ 89.14M	$ 75.80M	$ -278.92M	$ 94.94M
Financing Cash Flow	$ 880.00K	$ 12.87M	$ 3.29M	$ 340.05M	$ 366.00K

Currency in USD

Adaptimmune Therapeutics Earnings and Revenue History

Income Statement >

Adaptimmune Therapeutics Debt to Assets

Balance Sheet >

Adaptimmune Therapeutics Cash Flow

Cash Flow >

Adaptimmune Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing